Preliminary safety results from phase 1 and 2 studies have been reported for CSF1R inhibitor monotherapy in a variety of settings, including healthy subjects and patients with rheumatoid arthritis, cHL, or advanced solid tumors. This evidence concerns the gene CSF1R and classic Hodgkin lymphoma.